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Non clinical studies are one of the requirements for the Brazilian National Regulatory Authority, ANVISA,
for licensing a similar biotherapeutic product. During the WHO/KFDA workshop on implementing WHO
guidelines on evaluating similar biotherapeutic products (SBP) in Seoul, Republic of Korea, the Brazilian
experience with the non clinical studies of a Granulocyte Colony Stimulatory Factor (G-CSF), ﬁlgrastim,
was presented. The applicant presented a reduced non clinical data package, but the key studies with
relevant species were conducted and the non-clinical studies were considered sufﬁcient for approval.
Using the comparability exercise, these studies were taken together with the appropriate quality and
clinical packages presented.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
According to Brazil’s new regulations for biological products,
there are two pathways that could be used to license a similar
biotherapeutic product: the comparability pathway and the indi-
vidual development pathway [1]. The case presented during the
WHO/KFDA workshop on implementing WHO guidelines on eval-
uating similar biotherapeutic products refers to a G-CSF that was
licensed using the comparative pathway.
By using the comparative pathway, the applicant could reduce
the non-clinical data package. However, some general principles
should be followed.
The applicant must submit the following in-vivo studies: phar-
macodynamic studies relevant to the clinical indications which
sought cumulative toxicity studies, including a demonstration of
the toxicokinectic parameters using, two relevant species if
possible. If the two relevant species are not available, at least one
should be used. Local tolerance and immunotoxicity studies should
be presented when these are applicable. The most important study
must be comparative and designed to detect signiﬁcant differences
between the similar biological product and the comparator biologic
product.omescastanheira@yahoo.com.
ll rights reserved. The World HealthThe duration of toxicological studies must be sufﬁcient to detect
differences in immune response and toxicology between the
comparator biological product and the similar biological product.
Other toxicological studies, including pharmacology, reproduc-
tive toxicology, mutagenicity and carcinogenicity studies are
generally not required for biological products, unless indicated by
repeated toxicological studies.
For the case presented here from Brazilian regulations, the
application included different types of non clinical studies,
comparative and non comparative with different relevant species
and the studies were considered adequate for approval.
2. Review of non-clinical studies
Several different non clinical studies were presented by the
applicant. The two ﬁrst studies were repeat toxicity studies in rats:
one 90 day study using the similar G-CSF with 30 days recovery
time and the other was a dose repeated 45 day study in rats using
the originator biological product and 30 days recovery time. The
parameters observed during the two studies were PK and PD,
morbidity, mortality, clinical signs, body weight, food consumption,
hematology, biochemistry, and urinalysis. After the recovery
period, reversibility of all ﬁndings was observed.
While the studies were not head-to-head comparative studies
between the comparator and the originator biological product, the
applicant compared the results from the two studies and the result
from the ﬁrst study and the available literature data. The results
showed an adequate degree of comparability between the similarOrganization has granted the Publisher permission for the reproduction of this article.
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pharmacodynamic and toxic actions were broadly consistent with
that described for the originator product. No new toxic reactions
resulting from the similar G-CSF were observed compared to those
observed for the originator product and described in the scientiﬁc
literature.
The third study was an acute subcutaneous injection toxicity
study in rats with a 14-day observation period, using the similar G-
CSF. Mortality and clinical signs or reaction to the treatment, as
well as a detailed physical examination consisting of measuring
body weight, an Irwin screen, urine analysis, blood drug levels as
well as macroscopic observations and the histopathology, hema-
tology and biochemistry of the rat. No deaths during the course of
the study or treatment-related changes in the parameters exam-
ined, including those related to the central nervous system were
noted.
The fourth study presented was a 26-week subcutaneous
injection toxicity study in rats with a 4-week recovery time, using
the similar G-CSF. The observed parameters were clinical signs;
body weight; food consumption; ophthamology; hematology;
biochemistry; urinalysis; antibody production; gross observations
at necropsy; organ weight and histopathology.
The next study with the similar G-CSF used the same design of
the fourth study, but was conducted in monkeys.
Increases in white blood cell populations, consistent with the
pharmacological activity of G-CSF were observed at all dose levels.
Organ weight changes, macroscopic ﬁndings and microscopic
lesions attributed to the treatment with G-CSF were seen in both
study phases. Overall adverse effects had mostly resolved or had
a tendency towards reversibility following the recovery period. The
No-Observable-Adverse-Effect-Level (NOAEL) was established.
The last study was a comparative study using the similar and
original G-CSF; a 28 day immunological comparative study in rats
with a 15 day recovery period. The main parameters observed were
clinical signs, body weight, food and drink consumption,hematology, urinalysis, opthamological and auditory examination,
antibody determination, pharmacokinetic evaluation, pathology
and histopathology .The immunogenicity parameters included
qualitative IgG and IgM anti G-CSF assay, quantitative IgG anti G-
CSF and a G-CSF neutralizing antibody assay. The conclusion was
that no local intolerance effects were observed,
Immunogenicity was comparable between the similar and
originator biotherapeutic.
No differences between the similar and originator product were
observed in the safety proﬁle, toxicity or pharmacodynamic effects.3. Conclusion
The company presented a non clinical data package that was
considered sufﬁcient by ANVISA. Although not all of the studies
were comparative, the comparative studies presented were sufﬁ-
cient to demonstrate that there were no detectable and signiﬁcant
differences between the similar biological product and the
comparator biological product. The non comparative studies
provided relevant information about the similar G-CSF, which were
necessary for the following clinical study. It is important to note
that the non-clinical data were relevant and sufﬁcient. Taken
together, non-clinical and clinical data showed that the applicant’s
SBP GCSF was similar to the innovator’s reference product GCSF.
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